Stock EXPRS2 EXPRES2ION BIOTECH HOLDING AB
Add to a list
To use this feature you must be a member
Log inSign up

All News ExpreS2ion Biotech Holding AB

Equities

EXPRS2

SE0008348262

Market Closed - Nasdaq Stockholm
Other stock markets
 12:00:00 2024-07-12 pm EDT 		5-day change 1st Jan Change
1.108 SEK +3.55% Intraday chart for ExpreS2ion Biotech Holding AB -0.72% -47.49%
May. 16 ExpreS2ion Biotech Holding AB Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Apr. 16 ExpreS2ion Announces Completion of GLP Safety Study for ES2B-C001 (HER2-VLP) Breast Cancer Vaccine Candidate CI

All News

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
ExpreS2ion resolves on a directed issue of units to guarantors in connection with the completed rights issue
AQ
ExpreS2ion announces U.S. patent issue notification for glyco-engineered immunization antigens
AQ
ExpreS2ion announces final outcome of its rights issue
AQ
Rights issue subscription period ending 27 June 2024; subscription possible via form
AQ
ExpreS2ion announces poster presentation on the use of glycoengineered Drosophila S2 cells for production of highly immunogenic antigens at the ESACT meeting
AQ
Publication of clinical Phase Ib trial data for the adjuvanted RH5.1 blood-stage malaria vaccine
AQ
ExpreS2ion hosts informative webinar on 2024 Rights Issue and Highlights Key Updates on HER2+ Breast Cancer Vaccine
AQ
BioStock: Rights issue takes Expres2ion breast cancer vaccine to phase I
AQ
ExpreS2ion CEO to BioStock: "Compelling preclinical package gives us confidence"
AQ
The subscription period in ExpreS2ion's rights issue begins today
AQ
ExpreS2ion to present in upcoming investor and scientific events
AQ
ExpreS2ion publishes prospectus in connection with its rights issue of units
AQ
Bulletin from the Annual General Meeting of ExpreS2ion Biotech Holding AB held on 5 June 2024
AQ
ExpreS2ion Biotech : Interim report for January – March 2024 (Q1)
PU
ExpreS2ion announces financial results for the first quarter of 2024
AQ
ExpreS2ion Biotech Holding AB Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
ExpreS2ion to present in spring investor events
AQ
ExpreS2ion Biotech : Annual report 2023 including Auditor’s report
PU
ExpreS2ion annual report for 2023 published
AQ
Notice to attend the Annual General Meeting in ExpreS2ion Biotech Holding AB (publ)
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. EXPRS2 Stock
  4. News ExpreS2ion Biotech Holding AB